BioNTech Total Current Liabilities vs Total Stockholder Equity Analysis

BNTX Stock

USD 92.06 1.93 2.14%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Total Current Liabilities and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Total Current Liabilities vs Total Stockholder Equity

Total Current Liabilities vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Total Current Liabilities account and Total Stockholder Equity. At this time, the significance of the direction appears to have very strong relationship.

The correlation between BioNTech's Total Current Liabilities and Total Stockholder Equity is 0.82. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Total Current Liabilities and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of BioNTech SE are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Total Current Liabilities i.e., BioNTech's Total Current Liabilities and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on BioNTech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioNTech SE are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.

BioNTech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.76	0.82	0.85	1.0	0.98	0.62	-0.93	0.99	0.94	0.94	0.88	0.75	0.94	0.69	0.82	0.64	0.76	0.62	0.87	0.96	0.86	0.75	0.97	1.0	0.14
Short Long Term Debt Total	0.76		0.82	0.88	0.73	0.77	0.76	-0.58	0.68	0.73	0.58	0.59	0.4	0.57	0.78	0.53	0.82	0.43	0.58	0.87	0.66	0.89	0.4	0.74	0.77	0.56
Other Current Liab	0.82	0.82		0.99	0.79	0.72	0.34	-0.64	0.76	0.63	0.64	0.48	0.28	0.58	0.96	0.38	0.59	0.3	0.46	0.98	0.65	0.98	0.28	0.68	0.85	0.04
Total Current Liabilities	0.85	0.88	0.99		0.82	0.78	0.46	-0.68	0.79	0.7	0.67	0.56	0.36	0.63	0.94	0.47	0.67	0.38	0.55	1.0	0.7	1.0	0.36	0.75	0.88	0.14
Total Stockholder Equity	1.0	0.73	0.79	0.82		0.98	0.62	-0.95	1.0	0.95	0.95	0.9	0.78	0.95	0.65	0.83	0.63	0.78	0.61	0.85	0.97	0.84	0.78	0.97	0.99	0.13
Property Plant And Equipment Net	0.98	0.77	0.72	0.78	0.98		0.75	-0.93	0.98	0.98	0.94	0.94	0.82	0.96	0.58	0.88	0.69	0.82	0.64	0.8	0.98	0.8	0.82	0.99	0.97	0.27
Current Deferred Revenue	0.62	0.76	0.34	0.46	0.62	0.75		-0.53	0.6	0.8	0.55	0.79	0.72	0.63	0.27	0.79	0.69	0.74	0.62	0.46	0.67	0.49	0.72	0.77	0.59	0.74
Net Debt	-0.93	-0.58	-0.64	-0.68	-0.95	-0.93	-0.53		-0.95	-0.88	-1.0	-0.86	-0.74	-0.98	-0.44	-0.78	-0.55	-0.72	-0.49	-0.71	-0.98	-0.69	-0.74	-0.91	-0.92	-0.13
Retained Earnings	0.99	0.68	0.76	0.79	1.0	0.98	0.6	-0.95		0.95	0.96	0.91	0.8	0.97	0.61	0.85	0.59	0.8	0.62	0.82	0.97	0.81	0.8	0.97	0.99	0.09
Accounts Payable	0.94	0.73	0.63	0.7	0.95	0.98	0.8	-0.88	0.95		0.9	0.98	0.89	0.94	0.5	0.94	0.68	0.9	0.7	0.73	0.95	0.73	0.89	0.99	0.92	0.28
Cash	0.94	0.58	0.64	0.67	0.95	0.94	0.55	-1.0	0.96	0.9		0.87	0.76	0.98	0.44	0.8	0.55	0.75	0.49	0.71	0.99	0.68	0.76	0.92	0.93	0.14
Non Current Assets Total	0.88	0.59	0.48	0.56	0.9	0.94	0.79	-0.86	0.91	0.98	0.87		0.97	0.94	0.33	0.99	0.57	0.97	0.7	0.6	0.93	0.59	0.97	0.96	0.85	0.24
Non Currrent Assets Other	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97		0.87	0.15	0.99	0.41	1.0	0.69	0.41	0.82	0.41	1.0	0.87	0.71	0.15
Cash And Short Term Investments	0.94	0.57	0.58	0.63	0.95	0.96	0.63	-0.98	0.97	0.94	0.98	0.94	0.87		0.39	0.89	0.55	0.85	0.58	0.67	0.99	0.65	0.86	0.96	0.92	0.15
Net Receivables	0.69	0.78	0.96	0.94	0.65	0.58	0.27	-0.44	0.61	0.5	0.44	0.33	0.15	0.39		0.25	0.52	0.17	0.37	0.91	0.47	0.92	0.15	0.55	0.72	0.0
Good Will	0.82	0.53	0.38	0.47	0.83	0.88	0.79	-0.78	0.85	0.94	0.8	0.99	0.99	0.89	0.25		0.49	0.99	0.73	0.51	0.86	0.51	0.99	0.92	0.78	0.24
Common Stock Total Equity	0.64	0.82	0.59	0.67	0.63	0.69	0.69	-0.55	0.59	0.68	0.55	0.57	0.41	0.55	0.52	0.49		0.42	0.35	0.66	0.6	0.67	0.4	0.67	0.63	0.44
Short Term Investments	0.76	0.43	0.3	0.38	0.78	0.82	0.74	-0.72	0.8	0.9	0.75	0.97	1.0	0.85	0.17	0.99	0.42		0.72	0.43	0.81	0.43	1.0	0.87	0.71	0.16
Non Current Liabilities Total	0.62	0.58	0.46	0.55	0.61	0.64	0.62	-0.49	0.62	0.7	0.49	0.7	0.69	0.58	0.37	0.73	0.35	0.72		0.6	0.58	0.61	0.7	0.68	0.6	0.23
Inventory	0.87	0.87	0.98	1.0	0.85	0.8	0.46	-0.71	0.82	0.73	0.71	0.6	0.41	0.67	0.91	0.51	0.66	0.43	0.6		0.73	1.0	0.41	0.77	0.9	0.12
Other Current Assets	0.96	0.66	0.65	0.7	0.97	0.98	0.67	-0.98	0.97	0.95	0.99	0.93	0.82	0.99	0.47	0.86	0.6	0.81	0.58	0.73		0.71	0.82	0.97	0.94	0.23
Total Liab	0.86	0.89	0.98	1.0	0.84	0.8	0.49	-0.69	0.81	0.73	0.68	0.59	0.41	0.65	0.92	0.51	0.67	0.43	0.61	1.0	0.71		0.41	0.77	0.89	0.15
Long Term Investments	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97	1.0	0.86	0.15	0.99	0.4	1.0	0.7	0.41	0.82	0.41		0.87	0.71	0.14
Property Plant And Equipment Gross	0.97	0.74	0.68	0.75	0.97	0.99	0.77	-0.91	0.97	0.99	0.92	0.96	0.87	0.96	0.55	0.92	0.67	0.87	0.68	0.77	0.97	0.77	0.87		0.95	0.25
Total Current Assets	1.0	0.77	0.85	0.88	0.99	0.97	0.59	-0.92	0.99	0.92	0.93	0.85	0.71	0.92	0.72	0.78	0.63	0.71	0.6	0.9	0.94	0.89	0.71	0.95		0.12
Non Current Liabilities Other	0.14	0.56	0.04	0.14	0.13	0.27	0.74	-0.13	0.09	0.28	0.14	0.24	0.15	0.15	0.0	0.24	0.44	0.16	0.23	0.12	0.23	0.15	0.14	0.25	0.12

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Short Long Term Debt Total	68.9M	240.2M	301.5M	212.2M	219.1M	161.3M
Other Current Liab	16.4M	103.1M	3.0B	2.6B	1.3B	979.8M
Total Current Liabilities	138.1M	606.0M	3.5B	3.0B	2.1B	1.3B
Total Stockholder Equity	493.5M	1.4B	11.9B	20.1B	20.2B	21.3B
Other Liab	205.6M	97.1M	109.7M	283.9M	326.5M	166.9M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Property Plant And Equipment Net	148.1M	326.0M	520.4M	821.1M	971.6M	1.0B
Current Deferred Revenue	93.6M	391.5M	189.1M	77.1M	353.3M	371.0M
Net Debt	(450.2M)	(970.0M)	(1.4B)	(13.7B)	(11.4B)	(10.9B)
Retained Earnings	(424.8M)	(409.6M)	9.9B	18.8B	19.8B	20.8B
Accounts Payable	20.5M	102.3M	160M	204.1M	354M	371.7M
Cash	519.1M	1.2B	1.7B	13.9B	11.7B	12.2B
Non Current Assets Total	237.5M	651.7M	758.5M	1.4B	3.5B	3.7B
Non Currrent Assets Other	2K	1.0M	800K	6.5M	83.4M	87.6M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Long Term Debt	68.9M	231.0M	171.6M	176.2M	191M	116.1M
Cash And Short Term Investments	520.8M	1.3B	2.1B	14.1B	16.5B	17.4B
Net Receivables	20.2M	166.4M	12.4B	7.1B	2.3B	3.0B
Good Will	3.0M	53.7M	57.8M	61.2M	362.5M	380.6M
Common Stock Total Equity	166.8M	193.3M	232.3M	246.3M	283.3M	185.2M
Common Stock Shares Outstanding	211.5M	248.5M	259.7M	249.8M	242.7M	229.1M
Short Term Investments	1.7M	137.2M	381.6M	189.4M	4.9B	5.1B
Liabilities And Stockholders Equity	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Non Current Liabilities Total	166.0M	340.8M	455.5M	272.9M	689.9M	378.2M
Inventory	11.7M	64.1M	502.5M	439.6M	357.7M	190.9M
Other Current Assets	1.2M	61.0M	64.9M	271.9M	280.9M	294.9M
Other Stockholder Equity	(5.5M)	1.5B	(3.8M)	(5.3M)	1.2B	1.3B
Total Liab	304.2M	946.8M	3.9B	3.2B	2.8B	1.7B
Property Plant And Equipment Gross	148.1M	326.0M	594.6M	821.1M	1.2B	1.2B
Total Current Assets	560.2M	1.7B	15.1B	21.9B	19.5B	20.5B
Accumulated Other Comprehensive Income	691.5M	25.5M	1.8B	979.3M	(984.6M)	(935.4M)
Short Term Debt	7.6M	9.1M	129.9M	36M	28.1M	32.9M
Intangible Assets	86.5M	109.8M	144.6M	158.5M	804.1M	844.3M
Common Stock	232.3M	246.3M	246.3M	248.6M	285.9M	218.0M
Property Plant Equipment	116.0M	148.1M	326.0M	520.4M	598.5M	628.4M

Pair Trading with BioNTech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.

Moving against BioNTech Stock

0.71	ACRV	Acrivon Therapeutics Financial Report 14th of May 2024	Pair Corr
0.66	PULM	Pulmatrix Financial Report 10th of May 2024	Pair Corr
0.63	INDP	Indaptus Therapeutics	Pair Corr
0.62	FBRX	Forte Biosciences Financial Report 20th of May 2024	Pair Corr
0.46	RVMD	Revolution Medicines Financial Report 13th of May 2024	Pair Corr

The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.

The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:

How To Invest In BioNTech

Details

Is BioNTech Stock a good investment?

Details

What is BioNTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for BioNTech Stock analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.80)

Earnings Share

4.11

Revenue Per Share

15.873

Quarterly Revenue Growth

(0.65)

Return On Assets

0.0262

The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Total Current Liabilities vs Total Stockholder Equity Analysis

Total Current Liabilities vs Total Stockholder Equity

Total Current Liabilities vs Total Stockholder Equity Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Total Stockholder Equity

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Pair Trading with BioNTech

Moving against BioNTech Stock

Complementary Tools for BioNTech Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Inventory	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Retained Earnings	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Non Currrent Assets Other

Cash	- 1.0	Net Debt
Other Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Retained Earnings	- 0.95	Net Debt
Net Debt	- 0.95	Total Stockholder Equity
Net Debt	- 0.93	Property Plant And Equipment Net